Context: In France, over 170 000 persons benefit from opiate substitution treatment. The treatment delivery is most often assured by community pharmacies spread out throughout the territory. The aim of this study is to better know the continued care of individuals treated by methadone or high-dose buprenorphine in community pharmacies in Lille (North of France).
Method: This was a cross-sectional descriptive study with hand-delivered questionnaires. All pharmacies (n=65) in Lille were included.
Results: Fifty-eight of pharmacies (89%) responded to the survey and 55 of them (95%) followed patients treated by opiate substitution treatment. Addiction was considered as an illness by 53 of pharmacists (91%). Confidential discussions could only be conducted at one of every two treatment delivery work station.
Conclusion: Pharmacists are active in the continued care of individuals treated by opiate substitution treatment. They have a privileged relationship with the general practitioner. A rearrangement of pharmacies' premises could foster the development of therapeutic patient education within the pharmacy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2515/therapie/2013059 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl.
JAMA Netw Open
January 2025
San Francisco Department of Public Health, San Francisco, California.
Importance: The rise of high-potency opioids such as fentanyl makes buprenorphine initiation challenging due to the risks of precipitated withdrawal, prompting the exploration of strategies, such as low-dose initiation (LDI) of buprenorphine. However, no comparative studies on LDI outcomes exist.
Objective: To evaluate outpatient outcomes associated with 2 LDI protocols of buprenorphine among individuals with opioid use disorder (OUD) using fentanyl.
Mindfulness Training vs Recovery Support for Opioid Use, Craving, and Anxiety During Buprenorphine Treatment: A Randomized Clinical Trial.
JAMA Netw Open
January 2025
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.
Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.
Background: Women involved in the criminal legal system have elevated rates of opioid use disorder, which is treatable, and HIV, which is preventable with pre-exposure prophylaxis (PrEP). There are significant social and structural barriers to integrated delivery of PrEP and medications for opioid use disorder (MOUD), limiting women's ability to access these life-saving interventions. In a two parallel-arm randomized controlled trial, we are assessing an innovative eHealth delivery model that integrates PrEP with MOUD and is tailored to meet the specific needs of women involved in the criminal legal system.
View Article and Find Full Text PDFOpioid agonist therapy discontinuation in British Columbia: a cross-sectional study of people who access harm reduction services.
BMJ Open
January 2025
The University of British Columbia, Vancouver, British Columbia, Canada
Objectives: This study evaluates the prevalence and correlates of opioid agonist therapy (OAT) discontinuation across British Columbia (BC), using a sample of individuals who used substances and accessed harm reduction sites.
Design: This study uses data from the 2019 cross-sectional Harm Reduction Client Survey (HRCS).
Setting: The 2019 survey was administered from October to December at 22 harm reduction supply distribution sites across the 5 Regional Health Authorities of BC.
Immunogenicity persistence after four intramuscular triple-dose or standard-dose hepatitis B vaccine in patients receiving methadone maintenance treatment: A 1-year follow-up study in China.
Hum Vaccin Immunother
December 2025
School of Public Health, Shanxi Medical University, Taiyuan, Shanxi, China.
ClinicalTrials.gov (NCT03962816).https://clinicaltrials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!